Molecular Partners AG (MOLN)
6.11
-0.01
(-0.16%)
USD |
NASDAQ |
Nov 04, 13:37
Molecular Partners Enterprise Value: 26.06M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 26.06M |
| October 31, 2024 | 0.842M |
| October 30, 2024 | 27.06M |
| October 29, 2024 | 28.72M |
| October 28, 2024 | 37.34M |
| October 25, 2024 | 38.34M |
| October 24, 2024 | 22.74M |
| October 23, 2024 | 11.11M |
| October 22, 2024 | 40.99M |
| October 21, 2024 | 47.96M |
| October 18, 2024 | -15.42M |
| October 17, 2024 | -11.77M |
| October 16, 2024 | -12.76M |
| October 15, 2024 | -12.76M |
| October 14, 2024 | -19.40M |
| October 11, 2024 | -19.40M |
| October 10, 2024 | -19.40M |
| October 09, 2024 | -14.22M |
| October 08, 2024 | -14.22M |
| October 07, 2024 | -19.07M |
| October 04, 2024 | -10.44M |
| October 03, 2024 | -25.04M |
| October 02, 2024 | -23.38M |
| October 01, 2024 | -18.07M |
| September 30, 2024 | -8.214M |
| Date | Value |
|---|---|
| September 27, 2024 | -8.781M |
| September 26, 2024 | -21.39M |
| September 25, 2024 | -23.71M |
| September 24, 2024 | -10.60M |
| September 23, 2024 | -20.06M |
| September 20, 2024 | -22.05M |
| September 19, 2024 | -22.05M |
| September 18, 2024 | -16.41M |
| September 17, 2024 | -8.449M |
| September 16, 2024 | -4.135M |
| September 13, 2024 | -3.804M |
| September 12, 2024 | 6.483M |
| September 11, 2024 | 5.488M |
| September 10, 2024 | 9.138M |
| September 09, 2024 | 9.635M |
| September 06, 2024 | 5.819M |
| September 05, 2024 | 14.94M |
| September 04, 2024 | 19.16M |
| September 03, 2024 | 10.13M |
| August 30, 2024 | 11.46M |
| August 29, 2024 | 38.01M |
| August 28, 2024 | 33.03M |
| August 27, 2024 | 52.61M |
| August 26, 2024 | 28.38M |
| August 23, 2024 | 29.71M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-127.57M
Minimum
May 11 2022
884.52M
Maximum
Jan 14 2022
80.23M
Average
-40.20M
Median
Nov 21 2022
Enterprise Value Benchmarks
| AC Immune SA | 102.01M |
| CRISPR Therapeutics AG | 3.839B |
| Addex Therapeutics Ltd | 7.218M |
| NLS Pharmaceutics Ltd | 14.90M |
| MoonLake Immunotherapeutics | 2.430B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -16.68M |
| Revenue (Quarterly) | 1.715M |
| Total Expenses (Quarterly) | 19.38M |
| EPS Diluted (Quarterly) | -0.5086 |
| Profit Margin (Quarterly) | -972.4% |
| Earnings Yield | -32.26% |
| Normalized Earnings Yield | -32.31 |